Delivering therapies to the brain remains a major challenge due to the limited permeability of the blood-brain barrier. In a ...
Despite new methodologies and flexible regulatory pathways, CNS biopharmaceuticals still face significant safety assessment ...
Iopofosine I 131 Active in Treating Malignancies in the Brain; Confirmed Response in CNS Lymphoma Provides Additional Validation for Continued Development of Iopofosine in Multiple CNS Malignancies ...
DUBLIN--(BUSINESS WIRE)--The "Central Nervous System Therapeutics Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Central Nervous ...
Despite warnings, potentially inappropriate CNS-active medications are commonly prescribed to older adults — especially those with cognitive impairment — highlighting missed opportunities for safer ...
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence (AI) and machine learning (ML) platform to ...
Researchers analyzed the diagnostic value of stereotactic brain biopsy in patients with leukemia presenting central ...
FLORHAM PARK, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results